“We're probably exiting more in that mid to high single digits in Q4 as we go forward.”

In context

“n to eight. I'm just trying to do the math. I mean, it could be a little in the weeks, but I think investors getting confidence in the bioprocess outlooks important. I'm just wondering if these push outs don't come back in the fourth quarter, as you guys don't expect, is there some extra cushion in the bioprocess guide? Just want to get some color on that. Matt Gugino Yeah. Dan, like we talked about, we're a little bit north of $100 million that shifted primarily out of Q2 and Q3 into next year. That's a couple hundred basis points impact to bioprocessing growth for the full year. As we mentioned, there is some chance this moves back into Q4. That's not in our planning assumption today, but as you think about the progression through the year, we're talking about mid singles here for Q3. We're probably exiting more in that mid to high single digits in Q4 as we go forward. Dan Brennan Got it. Okay, thanks, Matt. Then sorry for a double dip here in bioprocess, I think it's fairly important. Just back to Leonard's question, just on any commonality in the customers. I know Rainer, you basically said it's a couple of resin push outs but is there anything from a therapeutic area or geographic area that together you think it's more of a market issue or really specific to a few molecules that you guys spec'd in on. Is there any reason why next year that wouldn't come back? I'm just thinking ahead if, say these customers' biologic script plans were coming in below plan, do they have recourse to say we're going to cut the expectation of what we need or any protections you guys might have on that? Thank you. Rainer M. Blair Dan, the commonality is really just aroun”